Quality of life in common variable immunodeficiency requiring intravenous immunoglobulin therapy

Annals of Allergy, Asthma and Immunology

Volumn 93, Issue 2, 2004, Pages 160-165

  Tcheurekdjian, Haig ^a   Palermo, Tonya ^b   Hostoffer, Robert ^b,c  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN;

ADULT; AGE; AGED; ARTICLE; COMMON VARIABLE IMMUNODEFICIENCY; COMORBIDITY; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DEMOGRAPHY; DIABETES MELLITUS; FEMALE; GENDER; HEALTH SURVEY; HUMAN; IMMUNOTHERAPY; MAJOR CLINICAL STUDY; MALE; NORMAL VALUE; PRIORITY JOURNAL; QUALITY OF LIFE; SHORT FORM 36; SOCIOECONOMICS;

EID: 4344693156     PISSN: 10811206     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1081-1206(10)61469-X     Document Type: Article

References (31)

1. Frost MH, Bonomi AE, Ferrans CE, Wong GY, Hays RD, Clinical Significance Consensus Meeting Group. Patient, clinician, and population perspectives on determining the clinical significance of quality-of-life scores. Mayo Clin Proc. 2002;77:488-494.
2. World Health Organization. The World Health Report 2001: Mental Health: New Understanding, New Hope. Geneva, Switzerland: World Health Organization; 2001.
3. Eiser C, Morse R. The measurement of quality of life in children: past and future perspectives. J Dev Behav Pediatr. 2001;22:248-256.
4. Health-related quality-of-life measures - United States, 1993. MMWR Morb Mortal Wkly Rep. 1995;44:195-200.
5. Guyatt GH, Feeny DH, Patrick DL. Measuring health-related quality of life. Ann Intern Med. 1993;118:622-629.
6. Centers for Disease Control and Prevention. Measuring Healthy Days. Atlanta, GA: CDC; 2000.
7. Landgraf JM, Abetz LN. Measuring health outcomes in pediatric populations: issues in psychometrics and application. In: Spilker B, editor. Quality of Life and Pharmacoeconomics in Clinical Trials. Philadelphia, PA: Lippincott-Raven Publishers; 1996:793-802.
8. Ware JE. The SF-36 Health Survey. In: Spilker B, editor. Quality of Life and Pharmacoeconomics in Clinical Trials. Philadelphia, PA: Lippincott-Raven Publishers; 1996:337-345.
9. Landgraf JM, Abetz L, Ware JE. The CHQ Users' Manual. Boston, MA: New England Medical Center, The Health Institute; 1996.
10. Ware JE, Snow KK, Kosinski M, Gandek G. SF-36 Health Survey Manual and Interpretation Guide. Boston, MA: New England Medical Center, The Health Institute; 1993.
11. Garratt A, Schmidt L, Mackintosh A, Fitzpatrick R. Quality of life measurement: bibliographic study of patient assessed health outcome measures. BMJ. 2002;324:1417-1421.
12. Hedderich U, Kratzsch G, Stephen W, Dichtelmuller H, Olischlager K, Heimpel H. Immunoglobulin substitution therapy in a patient with primary hypogammaglobulinaemia and anti-IgA antibodies. Clin Allergy. 1986;16:339-344.
13. Daly PB, Evans JH, Kobayashi RH, et al. Home-based immunoglobulin infusion therapy: quality of life and patient health perceptions. Ann Allergy. 1991;67:504-510.
14. Statistical and Economic Commission for Europe. Summary measures of population health and beyond: a look at US federal activities at measuring the health of populations. Paper presented at: Joint ECE/WHO Expert Meeting on Health Statistics Measurements; October 23-25, 2000; Ottawa, Ontario.
15. Sloan JA, Aaronson N, Cappelleri JC, Fairclough DL, Varricchio C, Clinical Significance Consensus Meeting Group. Assessing the clinical significance of single items relative to summated scores. Mayo Clin Proc. 2002;77:479-487.
16. Gardulf A, Bjorvell H, Gustafson R, Hammarstrom L, Smith CI. The life situations of patients with primary antibody deficiency untreated or treated with subcutaneous gammaglobulin infusions. Clin Exp Immunol. 1993;92:200-204.
17. Immune Deficiency Foundation. Primary immune deficiency diseases in America: the first national survey of patients and specialists. Available at: http://www.primaryimmune.org/pid/ patient_survey_publication.pdf. Accessed December 2, 2003.
18. Cunningham-Rundles C, Bodian C. Common variable immunodeficiency: clinical and immunological features of 248 patients. Clin Immunol. 1999;92:34-48.
19. Gaspar J, Gerritsen B, Jones A. Immunoglobulin replacement treatment by rapid subcutaneous infusion. Arch Dis Child. 1998;79:48-51.
20. Litzman J, Jones A, Hann I, Chapel H, Strobel S, Morgan G. Intravenous immunoglobulin, splenectomy, and antibiotic prophylaxis in Wiskott-Aldrich syndrome. Arch Dis Child. 1996;75:436-439.
21. Bousquet J, Knani J, Dhivert H, et al. Quality of life in asthma: internal consistency and validity of the SF-36 questionnaire. Am J Respir Crit Care Med. 1994;149:371-375.
22. Jacoby A, Baker GA, Steen N, Buck D. The SF-36 as a health status measure for epilepsy: a psychometric assessment. Qual Life Res. 1999;8:351-364.
23. Garratt AM, Ruta DA, Abdalla MI, Buckingham JK, Russell IT. The SF36 health survey questionnaire: an outcome measure suitable for routine use within the NHS? BMJ. 1993;306:1440-1444.
24. WHO Scientific Group. Primary immunodeficiency diseases. Clin Exp Immunol. 1995;99(Suppl):1-24.
25. Tarlov A, Ware J, Greenfield S, Nelson E, Perrin E, Zubkoff M. The Medical Outcomes Study: an application of methods for monitoring the results of medical care. JAMA. 1989;262:925-930.
26. Stewart A, Greenfield S, Hays RD, et al. Functional status and well-being of patients with chronic conditions: results from the Medical Outcomes Study. JAMA. 1989;262:907-913.
27. Hunt SA, Baker DW, Chin MH, et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). Available at: http://www.acc.org/clinical/ guidelines/failure/hf_index.htm. Accessed December 2, 2003.
28. Hermaszewski RA, Webster AD. Primary hypogammaglobulinaemia: a survey of clinical manifestations and complications. Q J Med. 1993;86:31-42.
29. Partanen J, Niskanen L, Lehtinen J, Mervaala E, Siitonen O, Uusitupa M. Natural history of peripheral neuropathy in patients with non-insulin-dependent diabetes mellitus. N Engl J Med. 1995;333:89-94.
30. Aghamohammadi A, Farhoudi A, Nikzad M, et al. Adverse reactions of prophylactic intravenous immunoglobulin infusions in Iranian patients with primary immunodeficiency. Ann Allergy Asthma Immunol. 2004;92:60-64.
31. Kavelaars A, Kuis W, Knook L, Sinnema G, Heijnen CJ. Disturbed neuroendocrine-immune interactions in chronic fatigue syndrome. J Clin Endocrinol Metab. 2000;85:692-696.